# Respiratory Syncytial Virus Infections FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/respiratory-syncytial-virus-infections

> 2 upcoming FDA catalysts in respiratory Syncytial Virus Infections: adjuvanted rsvpref3 vaccine (GSK) on Jan to Apr 2027 (topline data readout); adjuvanted rsvpref3 vaccine (GSK) on January 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 3, 2025 | [Rsvpref3 oa investigational vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725)) |
| July 24, 2025 | [Nirsevimab primary completion](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049)) |
| April 16, 2026 | [Nirsevimab topline data readout](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049?tab=results)) |
| June 23, 2026 | [Rsvpref3 oa investigational vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725?tab=results)) |
| July 20, 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT07220109 (A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220109)) |
| Sep to Dec 2026 | [Rsvpref3 oa vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT06534892 (An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534892)) |
| September 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | delayed | "NCT06534892 (An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534892)) |
| Jan to Apr 2027 | [Adjuvanted rsvpref3 vaccine topline data readout](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT07092865 (A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07092865)) |
| January 2027 | [Adjuvanted rsvpref3 vaccine primary completion](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT07092865 (A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07092865)) |

## Drugs

- [Rsvpref3 oa investigational vaccine](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) (GSK)
- [Nirsevimab](https://sec-api.dev/pdufa/nirsevimab) (AZN)
- [Rsvpref3 oa vaccine](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) (GSK)
- [Adjuvanted rsvpref3 vaccine](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/respiratory-syncytial-virus-infections.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Respiratory Syncytial Virus Infections FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/respiratory-syncytial-virus-infections

```bibtex
@misc{secapidev_indications_respiratory_syncytial_virus_infections_20261116,
  title        = {Respiratory Syncytial Virus Infections FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/respiratory-syncytial-virus-infections}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_respiratory_syncytial_virus_infections_20261116","title":"Respiratory Syncytial Virus Infections FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/respiratory-syncytial-virus-infections","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
